Decorte Future Industries is a Cambridge, UK-based deep tech company that extracts complex health data from sound.

Company history

Exoskeletons

Over the course of two years full-time work after his doctorate in ancient codebreaking, the company’s founder, Dr Roeland P-J E Decorte, invented, engineered, and brought to proof-of-concept the company’s initial technology - an exoskeleton that included AI controls and a novel biometric sensor architecture. The aim was to enable a new, efficient way to gather and upload human health data directly from human bodies into the cloud.

At the time just a one-man band, Decorte’s exoskeleton technology attracted the interest and ultimately endorsement of the UK Ministry of Defence and government in 2019-2020. Over the course of 2020, however, Decorte decided to move away from Defence and AI embedded in exoskeletons to focus on a version of the technology that was more accessible to the general public - where the greatest need for health monitoring and screening technology is.

Initial funding

In the summer of 2020, Decorte Future Industries was selected, uniquely for then still a one-person company, from thousands of startups worldwide to join Techstars’ London accelerator, thus successfully raising its first equity financing. Shortly after, the UK government decided to also invest in Decorte through its innovation grants arm, funding two successive testing phases of Decorte’s AI. During the Techstars programme, the company raised further capital from the co-founder and CTO of ARM, the CTO of IKEA, as well as other prominent US and UK-based investors.

Following this initial capital raise, Roeland started building out a wider team. Reaching out to sensor groups at the University of Cambridge, where the company was based, Decorte started recruiting doctoral students such as the company’s first CTO (Sep 2020 - Feb 2025) Erika Bondareva, and Dr Kayla Butkow, who were both working on sound-based approaches. Together the team set out a plan to go all-in on sound as the most promising and cost-effective way to extract human health data, overcoming the limitations and cost of traditional technologies which led to the creation of the exoskeletons. Head of Software Jasbir Singh, at the time one of the foremost developers in London, joined at the same time to create the cloud infrastructure for the AI systems.

SoNUS

Over two years of R&D, the company deployed and examined the capabilities of sound-based AI integrated into an exoskeleton-derived smart shirt prototype (Mark I, 2020-2021) and then built a scaled-down sound-based button device focused mainly on data gathering for AI training (Mark II, 2022). At this point, in May 2022, Decorte expanded its pre-seed round to $1.6M in total funding, with participation of London and Silicon Valley-based venture funds, to support further development.

The company used the data gathered by the Mark II devices to train and create AI models that would ultimately, in turn, become the earliest versions of Decorte’s Sound-based Natural Understanding System (SoNUS, 2023/2024 onward). In late 2023 and 2024, Decorte pushed to shift from SoNUS running on custom hardware to focus on deploying the AI primarily on smartphones. Late 2024 and early 2025, Decorte decided to overhaul the company’s original research-focused structure to a product-focused approach, resolving to massively accelerate development and release the first app using SoNUS in Q2 2025.

At present, Decorte has ongoing paid pilots with, amongst others, one of the world’s largest automotive manufacturers, and one of the world’s largest asset managers (with $5.8 trillion assets under management). Decorte has partnered with Apollo Hospitals, one of the largest healthcare providers in Asia, as well as with three US-based, and one EU-based, clinic, for data collection. Decorte is further working with insurers to bring its technology to the masses.

Leadership

Board & Investors

  • Dr Ashish Parikh

    Founder Heart and Vascular Clinics Newark, Middletown and Wilmington, American College of Cardiology, American Heart Association, American College of Physicians

    Chair of Clinical Advisory Board & Investor

  • Susan Standiford

    Former CTO @ IKEA, Former CTO @ Disney Online

    Board & Investor

    “Roeland and the DFI team are doing extremely interesting things for convergence science - they’re inventing and creating capabilities that will have broad effects on health monitoring across markets.

  • Mike Muller

    Co-Founder & Former CTO ARM

    Investor

    “I’m excited to see products and services that can help address the pressing problems of cost and quality in care. These issues will only increase in the coming years with our changing demographics and pressure on health care budgets.“

  • Dr Gordon Hollingworth

    CTO Raspberry Pi

    Board

    “The Decorte team have built an unrivalled technology suite in their mission to democratise access to complex health data. Having been part of their journey from the very beginning I have no doubt they are headed for tremendous success.”

  • Eamonn Carey

    MD Techstars London, GP Tera Ventures, GP The Fund

    Board & Investor

    “I saw Roeland for the first time on the BBC and was immediately struck by their personality and character and passion for what they were building. As we were getting feedback from external assessors and people who were looking at the pitches, I got a number of messages saying we would be insane not to invest in this company. And I agreed - I have been writing and tweeting and talking about the need for this kind of tech for ages.”

  • Trupen Modi

    Sr Director of Digital Healthcare @ Microsoft

    Board Observer & Investor

    “The Decorte team have built a market differentiator product that will transform the healthtech landscape. Integrating with existing infrastructure, their unique AI can identify and monitor alignments, resulting in efficient data collection as well as early detection and intervention. I personally believe this team is extremely talented and will generate substantial revenue.”

  • Hugo Chardon

    Co-founder AMROCK Ventures

    Board Observer & Investor

    “Decorte is revolutionizing the way to listen to the human body. Their foundational AI which uses Machine Learning algorithms to extract human biometric data directly from audio is ground-breaking and opens up various commercial avenues.”